











WEBINAR SERIES:

Regulatory Approaches for Agricultural Applications of Animal Biotechnology

Session 2 • September 2020





Summary of Day 1 of Session 2: Regulatory approaches to Genome Edited Livestock

Australia Lisa Kelly

Argentina Agustina Whelan

Brazil Rubens Nascimento

Japan Mai Tsuda (Ryo Ohsawa)

Norway Arne Holst-Jensen

African Union Silas Obukosia

Kenya Dornington Ogoyi

South Africa Hennie Groenewald

Argentina/Brazil Agustina & Maria Dagli - some real examples

Are the current regulations / standards fit for purpose / out of date ?

Lisa

Why the review?



- Unclear if foods derived using NBTs are captured by current definitions
- FSANZ constrained from providing interpretive advice in relation to the scope of definitions

Arne

Key review questions:

- are the definitions in the Australia New Zealand Food Standards Code for 'food produced using gene technology' and 'gene technology' fit for purpose given the emergence of NBTs
- is pre-market safety assessment of NBT foods justified based on risk

17/09/2020



The Gene Technology Act (Genteknologiloven) regulates contained use and release of GMOs

- Law entered into force in 1993
- almost unchanged since
- Is it adequate for present technological and political realities?
 - especially in light of genome editing?





- ascertain applicability of existing legislation

• The regulations are sufficient (esp. in relation to Cartagena Protocol)

Hennie

Findings



 GMO Act <u>sufficient</u> > regulation <u>threshold</u> = genetic variation beyond that which may occur naturally.

Mai (Ryo)

Environmental Safety of Genome-Edited organisms under the Cartagena Act

In February 2019,

the Japanese government defined genome-edited final products derived by modifications of SDN-1 type (directed mutation without using a DNA sequence template) as not representing "living modified organisms"

according to the Japanese Cartagena Act.

Martin

LMO definition from Cartagena Protocol

- "Living modified organism" means any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology;
- ♦ "Modern biotechnology" means the application of:
- a. In vitro nucleic acid techniques, including recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles, or
- b. Fusion of cells beyond the taxonomic family,

that overcome natural physiological reproductive or recombination barriers and that are not techniques used in traditional breeding and selection;

Definitions are the key

Martin

LMO definition from Cartagena Protocol

- *"Living modified organism" means any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology;
- "Modern biotechnology" means the application of
- a. In vitro nucleic acid techniques, including recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles, or
- Fusion of cells beyond the taxonomic family,

that overcome natural physiological reproductive or recombination barriers and that are not techniques used in traditional breeding and selection;

Lisa

Next steps - revising definitions

- P1055 Definitions for gene technology and new breeding techniques
- Work commenced in February 2020
- First public consultation in early 2021

Objectives for amending the definitions:

Improve clarity about what foods are captured for premarket approval

Better accommodate new and emerging technologies (future proofing)

Regulate NBT foods in a manner that is commensurate with the risks they pose

Maria

Definition of GMO by the brazilian biosafety law 11.105


- · Article 3. Under this Law, it shall be considered:
- I an organism: each and every biological entity that is capable of reproducing or transferring genetic material, including virus and other classes that may be made known;
- II deoxyribonucleic acid DNA, ribonucleic acid RNA: genetic material which contains determining information about transmissible hereditary characters to progeny;
- III recombinant DNA/RNA molecules: molecules manipulated outside live cells through changes made to natural
 or synthetic DNA/RNA segments that can multiply in a live cell, or yet, DNA/RNA molecules resulting from this
 multiplication; DNA/RNA synthetic segments equivalent to natural DNA/RNA are also considered;
- IV genetic engineering: the activity of manipulating DNA/RNA recombinant molecules;
- V genetically modified organism GMOs: an organism the genetic material of which DNA/RNA has been modified by any genetic engineering technique:
- VI –GMO by-product: a product obtained from a GMO and that is not capable of autonomously replicating, or that
 does not contain a feasible GMO form;
- VII human germinal cell: the mother cell responsible for forming gametes which are found in the female and male sexual glands and their direct progeny in any ploid degree;
- VIII cloning: an asexual reproduction process, artificially produced, based on a sole genetic patrimony, by using or not genetic engineering techniques;
- IX cloning for reproductive means: cloning the end purpose of which is to make an individual;
- X therapeutic cloning: cloning the end purpose of which is to produce embryonic stem cells for therapeutic
 purposes;
- · XI embryonic stem cells: embryonic cells that are capable of modifying the cells of any organism tissue.

8


• Barriers to innovation = loss of potential benefit



- Risk is the key real / measurable / perceived
- How to use science to correctly evaluate risk?



Silas




Is benefit a consideration?

Arne Sustainability Non-safety criteria: Societal benefits **Ethics** Health Safety criteria: **Environment**

- What is the trigger for regulation?
 - Process
 - Product
- What level of regulation is appropriate?
 - Risk tiering

Public confidence is essential




NEW Breeding Technologies – implication: breeding is a technology?

Hennie



Agustina



Arne

